Each report covers a single therapy in a single indication, published within days of approval. A free two page executive summary is available for every published report.
Full reports are 25 pages, delivered as a PDF, with internal team sharing included.
FDA approval on 15 October 2026 made Enspryng the first thyroid eye disease therapy that patients can inject themselves at home. The report assesses whether convenience can win share from an established intravenous market leader, despite a missed primary endpoint in one pivotal trial.
Coverage is selected from recent FDA and EMA approvals and Phase III readouts with meaningful commercial questions. Reports are added here as they enter production.
Download any free executive summary to be notified the day the next report is published.
We accept a limited number of custom reports, using the same structure and methodology as our published reports. Tell us the product, the indication and your deadline.